AstraZeneca budgets another $2B to boost manufacturing and R&D in US
Among a flurry of third-quarter updates on Tuesday, AstraZeneca said it is earmarking an additional $2 billion to add 1,000 new jobs in the US. This is on top of the ...
View ArticleBayer not eyeing new deals to address Xarelto sales erosion
Bayer reiterated its plans to ride out the generic-driven sales decline of its thrombosis drug Xarelto, as the company’s shares plummeted to a record low because of lackluster third-quarter earnings....
View ArticleAstraZeneca, Daiichi Sankyo replace lung cancer filing for Enhertu successor
AstraZeneca and Daiichi Sankyo are changing the approval submission strategy for its planned Enhertu successor, datopotamab deruxtecan (Dato-DXd), after a few missed trials. The companies voluntarily...
View ArticleExclusive: GV-backed Medicaid startup Diverge Health raises $52M
A startup that helps low-income Medicaid members get the care they need and supports the doctors who work with them has raised $52 million, it confirmed to Endpoints News. Alphabet's venture arm GV led...
View ArticleApollo makes a deal worth up to $926M; Abeona resubmits gene therapy
Plus, news about Centessa, Autolus Therapeutics, Zucara Therapeutics, Vindur Tx, Vittoria Biotherapeutics and the MD Anderson Cancer Center: Apollo Therapeutics’ cardio-metabolic pact: The company will...
View ArticleMerck KGaA plans China submission after late-stage win for tumor drug
Merck KGaA’s experimental treatment for patients with tenosynovial giant cell tumors hit the primary endpoint in a Phase 3 study, and the company plans to submit the drug for approval in China with its...
View ArticleFDA commissioner warns of risk to agency under RFK Jr. influence
With just a few months to go before he likely steps down, President Biden's FDA Commissioner Rob Califf weighed in on how the agency might be affected by the incoming administration. Califf, while not...
View ArticleFDA denies Ocaliva full approval, but Intercept hopes to keep drug on market
The FDA rejected the full approval submission for Intercept Pharmaceuticals and Alfasigma’s primary biliary cholangitis treatment Ocaliva after safety concerns dogged the product, casting its future...
View ArticleMerck, AstraZeneca tout Phase 3 win for Koselugo in neurofibromatosis
Merck and AstraZeneca are hoping to expand the label of their MEK inhibitor Koselugo to certain adult patients with neurofibromatosis type 1 following a successful Phase 3 study. The companies
View ArticleSyndax's menin inhibitor succeeds in pivotal trial, but investors aren't...
Syndax Pharmaceuticals said its experimental menin inhibitor met the primary endpoint in a pivotal trial for certain leukemia patients, and it's planning a regulatory filing in the first half of 2025....
View ArticleAstraZeneca CEO reaffirms commitment to China following executive's detention
NEW YORK — AstraZeneca is not backing away from China despite an investigation into its president of China operations. As the company reported its third-quarter earnings, questions continued to swirl...
View ArticlePfizer looking to sell hospital drugs unit — reports
Pfizer is reportedly shopping its hospital drugs unit as it fends off scrutiny from activist investor Starboard Value. The plan was reported Tuesday by Reuters, which said Pfizer had tapped Goldman ...
View ArticleSyros' shares plummet as blood cancer drug fails again
Syros Pharmaceuticals’ share price nosedived after its last drug candidate flunked a trial in hematological malignancies for the second time in recent months. In a 190-participant Phase 3 trial, the...
View ArticleBioNTech buys out partner Biotheus for PD-L1/VEGF cancer drug
After initially promising more than $1 billion in biobucks to its partner Biotheus for a single drug, BioNTech is now buying out all of the China-based company for $800 million in cash and as much ...
View ArticleExclusive: Flagship names two CEO-partners to lead Valo Health, Apriori Bio
Flagship Pioneering has appointed two new CEO-partners to advise its portfolio companies and help steer its spinouts Apriori Bio and Valo Health, the life sciences incubator and investor told Endpoints...
View ArticleTRexBio raises $84M to take in-house immune program into the clinic
Bay Area immunology biotech TRexBio has raised a $84 million Series B to start clinical studies of a potential treatment for atopic dermatitis and ulcerative colitis. The biotech’s lead candidate,...
View ArticleAfter stock slides, Amgen addresses bone density talk on obesity drug
A lot of Amgen's future rides on its experimental obesity medicine MariTide. At least in the minds of investors. Ahead of the biopharma's most critical readout later this year — a Phase 2 study of the ...
View ArticleOtsuka and ICU Medical forge IV manufacturing network to supply the US
Otsuka Pharmaceutical Factory is paying $200 million to the medical equipment company ICU Medical for an alliance to supply IV products to the US. The joint venture will have a combined capacity of 17...
View ArticleMetsera raises $215M for studies of GLP-1 and amylin obesity drugs
Just seven months after unveiling with $290 million, obesity biotech Metsera is back with another $215 million. The New York-based company will use the Series B funds to support a recently started ...
View ArticlePrimary care unicorn startup Forward Health shuts down
Forward Health, a primary care clinic startup that hoped to make healthcare visits more accessible via "CarePods" in public spaces such as malls, has shut down. Patients got unlimited visits to...
View Article